This article is sponsored by Revvity. By Anis H Khimani, PhD, Senior Strategy Leader, Life Sciences strategy group, Revvity, Inc. Across the biotherapeutics workflow The landscape of large molecule drug development has evolved significantly in recent decades. As the significance of large molecules continues to broaden across diverse modalities, emphasis on bispecific and multispecific antibodies […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!